Active substanceAmitriptylineAmitriptyline
Similar drugsTo uncover
  • Amitriptyline
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Amitriptyline
    pills inwards 
    ALSI Pharma, ZAO     Russia
  • Amitriptyline
    pills inwards 
    ZIO-HEALTH, JSC     Russia
  • Amitriptyline
    solution w / m in / in 
  • Amitriptyline
    pills inwards 
  • Amitriptyline
    pills inwards 
    OZONE, LLC     Russia
  • Amitriptyline
    solution w / m in / in 
  • Amitriptyline Grindeks
    pills inwards 
    GRINDEX, JSC     Latvia
  • Amitriptyline Zentiva
    pills inwards 
    Zentiva as.     Czech Republic
  • Amitriptyline Zentiva
    solution w / m 
    Zentiva c.s.     Czech Republic
  • Amitriptyline Nycomed
    pills inwards 
    Takeda Pharma A / S     Denmark
  • Amitriptyline-AKOS
    solution w / m 
  • Amitriptyline-Ferein
    pills inwards 
    BRYNTSALOV-A, CJSC     Russia
  • Vero-Amitriptyline
    pills inwards 
    VEROPHARM SA     Russia
  • Saroten retard
    capsules inwards 
    H. Lundbeck A / S     Denmark
  • Dosage form: & nbspsolution for intramuscular injection
    Composition:

    Each ampoule (2 ml) contains:

    Active substance: amitriptyline 20 mg (as amitriptyline hydrochloride 22.63 mg);

    Excipients: glucose (dextrose) - 80,00 mg, water for injection - up to 2 ml.

    Description:

    A clear, colorless solution.

    Pharmacotherapeutic group:Antidepressant
    ATX: & nbsp

    N.06.A.A.09   Amitriptyline

    Pharmacodynamics:

    Amitriptyline is a tricyclic antidepressant from a group of indiscriminate inhibitors of neuronal capture of monoamines.

    Pharmacodynamics

    It also has some analgesic (central genesis), H2-histamine-blocking and antiserotonin action, helps to eliminate night incontinence and reduces appetite.

    Has a strong peripheral and central anticholinergic action due to high affinity for m-holinoretseptoram; a strong sedative effect associated with affinity for H1-histamine receptors, and alpha-adrenoblocking action. Has the properties of antiarrhythmic drugs of the subgroup la, like quinidine in therapeutic doses, slows down the ventricular conduction (in case of an overdose it can cause severe intragastric blockade).

    The mechanism of antidepressant action is associated with an increase in the concentration norepinephrine in synapses and / or serotonin in the central nervous system (CNS) (reducing their reverse absorption). Accumulation of these neurotransmitters occurs as a result of inhibition of their inverse capture by the membranes of presynaptic neurons. With prolonged use reduces the functional activity of beta-adrenergic and serotonin receptors in the brain, normalizes adrenergic and serotonergic transmission, restores the balance of these systems, disturbed in depressive states. With anxiety-depressive states reduces anxiety, agitation and depressive manifestations.

    The mechanism of antiulcer action is due to the ability to block H2-histamine receptors in parietal cells of the stomach, and also have sedative and m-holinoblokiruyuschee action (with peptic ulcer of the stomach and 12 duodenal ulcer relieves pain, helps to accelerate the healing of ulcers). The efficacy of bedwetting is probably due to anticholinergic activity, leading to an increase in the capacity of the bladder to stretch, direct beta-adrenergic stimulation, activity alpha-adrenergic agonists, accompanied by increased sphincter tone, and central blockade of the capture of serotonin.

    Has a central analgesic effect, which is believed to be associated with changes in the concentration of monoamines in the central nervous system, especially serotonin, and influence on endogenous opioid systems.

    The mechanism of action for bulimia nervosa is unclear (it may be similar to that in depression). It shows a distinct effect of the drug with bulimia in patients with both depression and its presence, while a decrease in bulimia can be noted without the concomitant weakening of depression itself.

    When general anesthesia reduces blood pressure and body temperature. Does not inhibit MAO. Antidepressant effect develops within 2-3 weeks after the beginning of application.

    Pharmacokinetics:

    Bioavailability of amitriptyline for various routes of administration is 30-60%, its active metabolite nortriptyline 46 - 70%. Volume of distribution 5-10 l / kg. Effective therapeutic concentrations in the blood of amitriptyline 50 - 250 ng / ml, for nortriptyline (its active metabolite) 50 - 150 ng / ml. The maximum concentration in the blood plasma (Cmax) - 0.04-0.16 μg / ml.Passes through the histohematological barriers, including the blood-brain barrier (including nortriptyline). The concentration of amitriptyline in tissues is higher than in plasma. Relationship with plasma proteins 92 - 96%. Metabolised in the liver (by demethylation, hydroxylation) with the formation of active metabolites - nortriptyline, 10-hydroxy-amitriptyline, and inactive metabolites.

    The half-life of plasma from 10 to 28 hours for amitriptyline and 16 to 80 hours for nortriptyline. It is allocated by the kidneys - 80%, partially with bile. Total withdrawal within 7-14 days.

    Amitriptyline penetrates the placental barrier, is excreted in breast milk in concentrations similar to plasma.

    Indications:

    Depression (especially with anxiety, agitation and sleep disorders, including in childhood, endogenous, involutional, reactive, neurotic, drug, with organic brain damage, alcohol withdrawal), schizophrenic psychoses, mixed emotional disorders, behavioral disorders (activity and attention ), nocturnal enuresis (except for patients with bladder hypotension), bulimia nervosa, chronic pain syndrome (chronic pain in cancer patients, migraine, rheumatic diseases, atypical pain in t he area face,postherpetic neuralgia, posttraumatic neuropathy, diabetic or other peripheral neuropathy), headache, migraine (prophylaxis), peptic ulcer and duodenal ulcer.

    Contraindications:

    Hypersensitivity to the components of the drug;

    Use together with MAO inhibitors and 14 days before the start of treatment;

    Myocardial infarction (acute and recovery periods);

    Acute alcohol intoxication;

    Acute intoxication with sleeping pills, analgesic and psychoactive drugs;

    Closed glaucoma;

    Severe disorders of atrioventricular (AV) and intraventricular conduction (AV blockade II degree, blockade of the legs of the bundle of His);

    Lactation period (breastfeeding);

    Children under 12 years.

    Carefully:

    Carefully should be applied amitriptyline in people with alcoholism, with bronchial asthma, manic-depressive psychosis (MDP) and epilepsy (see Special instructions), with oppression of bone marrow hematopoiesis, hyperthyroidism, angina pectoris and heart failure, intraocular hypertension, schizophrenia (although it usually does not occur exacerbationsproductive symptoms), pregnancy (especially I trimester).

    Dosing and Administration:

    Assign intramuscularly.

    In severe depression, resistant to therapy: intramuscularly (inject slowly!) Is administered at a dose of 10 - 20 - 30 mg to 4 times a day, increasing the dose should be carried out gradually, the maximum daily dose of 150 mg; After 1 - 2 weeks they switch to taking the drug inside. Children over 12 years of age and elderly people are given lower doses and increase them more slowly. If the patient's condition does not improve within 3-4 weeks of treatment, then further therapy is impractical.

    Side effects:

    Basically, they are associated with the anticholinergic action of the drug: paresis of accommodation, blurred vision, increased intraocular pressure, dry mouth, constipation, intestinal obstruction, delayed urination, fever. All these phenomena usually pass after adaptation to the drug or reduce doses.

    From the side of the central nervous system: headache, ataxia, fatigue, weakness, irritability, dizziness, tinnitus, drowsiness or insomnia, impaired concentration, nightmarish dreams, dysarthria,confusion, hallucinations, motor agitation, confusion, tremor, paresthesia, peripheral neuropathy, changes in the EEG. Rarely, extrapyramidal disorders, convulsions, anxiety.

    From the cardiovascular system: tachycardia, arrhythmia, conduction disorders, lability of arterial pressure, expansion of the complex QRS on ECG (violation of intraventricular conduction), symptoms of heart failure, fainting.

    From the digestive tract: nausea, vomiting, heartburn, anorexia, stomatitis, taste disturbance, darkening of tongue, epigastric discomfort, gastralgia, increased activity of "liver" transaminases, rarely cholestatic jaundice, diarrhea.

    From the endocrine system: an increase in the size of the mammary glands in men and women, galactorrhea, changes in the secretion of antidiuretic hormone (ADH), changes in libido, potency. Rarely - hypo- or hyperglycemia, glucosuria, impaired glucose tolerance, edema of the testicles.

    Allergic reactions: skin rash, itching, photosensitivity, angioedema, urticaria.

    Other: agranulocytosis, leukopenia, eosinophilia, thrombocytopenia,purpura and other blood changes, hair loss, enlarged lymph nodes, weight gain with prolonged use, sweating, pollakiuria.

    With prolonged treatment, especially in high doses, with a sudden cessation of treatment, the syndrome of "withdrawal" may develop: headache, nausea, vomiting, diarrhea, as well as irritability, sleep disturbance with bright, unusual dreams, increased excitability.

    Overdose:

    Drowsiness, disorientation, confusion, depression of consciousness down to coma, dilated pupils, fever, dyspnea, dysarthria, agitation, hallucinations, convulsive attacks, rigidity of muscles, vomiting, arrhythmia, arterial hypotension, heart failure, respiratory depression.

    Measures of assistance: cessation of therapy with amitriptyline, fluid infusion, symptomatic therapy, maintenance of blood pressure and water-electrolyte balance. The monitoring of cardiovascular activity (UE) has been shown for 5 days, since relapse may occur after 48 hours and later.Hemodialysis and forced diuresis are of little effect.

    Interaction:

    Amitriptyline strengthens the depressing effect on the central nervous system following drugs: neuroleptics, sedatives and hypnotics, anticonvulsant drugs, analgesics, funds for anesthesia, alcohol; shows synergism when interacting with other antidepressants.

    With the combined use of amitriptyline with neuroleptics and / or anticholinergic drugs, a febrile temperature reaction may occur, paralytic intestinal obstruction.

    Amitriptyline potentiates the hypertensive effects of catecholamines and other adrenostimulants, which increases the risk of heart rhythm disturbances, tachycardia, severe arterial hypertension, but inhibits the effects of drugs that affect the release of norepinephrine.

    Amitriptyline may reduce the antihypertensive effect of guanethidine, drugs with a similar mechanism of action, and weaken the effect of anticonvulsants.

    With the simultaneous use of amitriptyline: and anticoagulants - coumarin derivatives may increase the anticoagulant activity of the latter.

    With the simultaneous administration of amitriptyline and tsemethidine, an increase in plasma concentration of amitriptyline with possibledevelopment of toxic effects. Inducers of microsomal liver enzymes (barbiturates, carbamazepine) reduce the plasma concentrations of amitriptyline.

    Amitriptyline increases the effect of antiparkinsonian drugs and other drugs that cause extrapyramidal reactions.

    Quinidine slows the metabolism of amitriptyline. Amitriptyline with disulfiram and other acetaldehyde dehydrogenase inhibitors may trigger delirium. Estrogen-containing oral contraceptives can increase the bioavailability of amitriptyline; pimozide and probucol may increase cardiac arrhythmias.

    Amitriptyline may increase depression caused by glucocorticosteroids; joint use with drugs to treat thyrotoxicosis increases the risk of agranulocytosis.

    Simultaneous administration of amitriptyline with MAO inhibitors can lead to death. A break in treatment between taking MAO inhibitors and tricyclic antidepressants should be at least 14 days!

    Special instructions:

    Amitriptyline in doses above 150 mg / day reduces the threshold of convulsive activity,therefore, one should consider the possibility of the occurrence of convulsive seizures in patients with those in the history and in the category of patients who are predisposed to this because of age or trauma.

    Treatment with amitriptyline in old age should be carefully controlled, with minimum doses of the drug and gradually increased, in order to avoid the development of delirious disorders, hypomania and other complications.

    Patients with a depressive TIR phase can go into a manic stage.

    Effect on the ability to drive transp. cf. and fur:

    During the reception of amitriptyline, driving of vehicles, maintenance of mechanisms and other types of work requiring increased concentration of attention, as well as alcohol intake are prohibited.

    Form release / dosage:

    Solution for intramuscular injection 10 mg / ml.

    Packaging:2 ml per ampoule of colorless glass. 5 ampoules per container of PVC. Two containers (10 ampoules), together with instructions for use, are placed in a cardboard box.
    Storage conditions:In a dry, dark place at a temperature of 10 to 25 ° C.
    Shelf life:

    3 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:П N015860 / 01
    Date of registration:26.06.2009 / 01.11.2012
    Expiration Date:Unlimited
    Date of cancellation:2014-12-23
    The owner of the registration certificate:Zentiva c.s.Zentiva c.s. Czech Republic
    Manufacturer: & nbsp
    ZENTIVA, k.s. Czech Republic
    Representation: & nbspZENTIVA ZENTIVA Czech Republic
    Information update date: & nbsp13.09.2017
    Illustrated instructions
      Instructions
      Up